Compliance Question of the Week – General

A patient is receiving an infusion treatment in which three different medications are administered simultaneously through a multi-lumen IV line. According to the AMA CPT guidelines, would this scenario be coded as a concurrent infusion (CPT 96368), and what key factors should be documented to support this code? Additionally, how would coding differ if the medications were mixed in a single bag instead of administered through separate IV piggy-backs?

How should an IV infusion lasting 2 hours and 10 minutes be billed if no additional infusion hour is warranted? Should an IV push charge be reported for the additional 10 minutes of the infusion?

Under what circumstances does Medicare provide coverage for drugs or biologicals, and how is the determination made regarding whether a drug is considered “not usually self-administered”?

How should the administration of an IV infusion lasting longer than 1 hour but less than 91 minutes be reported? At what point should the code 96415 be used for “each additional hour” of infusion?

How should the administration of an IV infusion lasting longer than 1 hour but less than 91 minutes be reported? At what point should the code 96415 be used for “each additional hour” of infusion?

Will reporting codes 96372 and 96373 be impacted by the determination of the primary or secondary intent of the encounter?

What criteria must be met when using 96374 with 96375?

What codes do we report for monoclonal antibody Beyfortus™?

What factors should be documented when determining whether an antineoplastic agent is being administered for cancer or another cause?

From a claims perspective, what are some red flags when reviewing infusion and injection claims?

Why can’t we code 95180 (rapid desensitization) and chemotherapy drug administration codes together when we perform carboplatin desensitization?

What is the difference between white bagging and brown bagging regarding patient-supplied drugs?